Patient, disease, treatment, and response demographics for the patient cohort
| No. . | Age at Dx, y; sex . | Pathology . | Treatment and response . | PET DS prior to RT . | RT dose, Gy . | Progression field (RT) . |
|---|---|---|---|---|---|---|
| 1 | 62; M | DLBCL: GCB subtype | R-CHOP ×6 > PR > salvage RT to head/neck* | 4 | 45 | Out |
| 2 | 75; M | DLBCL: GCB subtype | R-CHOP ×6 > PR > salvage RT to mediastinum† | 5 | 50 | Ongoing remission |
| 3 | 59; F | DLBCL: transformed FL | Prior multiply-relapsed FL including CHOP ×6 > transformation DLBCL > salvage chemotherapy and autograft > PD > EPOCH ×1 > CR > PD > salvage RT to S1 nerve root* | 5 | 10 (planned 44) | In/out |
| 4 | 76; M | DLBCL: GCB subtype | R-CHOP ×6 > PD > salvage RT to cecal mass† | 5 | 45 | In/out |
| 5 | 74; F | DLBCL: transformed FL | Prior FL CHOP ×6 > CR > transformation DLBCL > R-CEOP ×6 > PD > salvage RT to abdominal node‡ | 5 | 30.6 | Ongoing remission |
| 6 | 70; M | DLBCL: ABC subtype + double expressor | R-EPOCH ×6 > PD > salvage RT to maxillary progression† | 5 | 32.4 (planned 36) | Out |
| 7 | 74; M | DLBCL: ABC subtype | R-CHOP ×6 > PD > salvage RT to axilla† | 5 | 44 | Out |
| 8 | 42; M | DLBCL: GCB subtype + double expressor | R-CHOP ×3 > PD > salvage RT to inguinal node† | 5 | 50 | In/out |
| 9 | 78; F | DLBCL: GCB subtype | R-CHOP ×6 > CR > PD > salvage RT to mediastinum‡ | 5 | 40 | Ongoing remission |
| 10 | 53; M | HGBL with MYC and BCL2 and/or BCL6R | R-EPOCH ×6 > PR > salvage RT to paratracheal node‡ | 4 | 40 | Ongoing remission |
| 11 | 70; M | DLBCL: transformed FL | Prior FL > R-bendamustine > PR > PD transformation to DLBCL > salvage RT to parotid node† | 5 | 50.4 | Ongoing remission |
| 12 | 67; F | DLBCL: T cell/histiocyte rich | R-CHOP ×6 > CR > PD > GemOx > CR > PD > salvage RT to C7 vertebra* | 5 | 40 | Out |
| 13 | 48; M | DLBCL: transformed FL | Prior FL > R-CHOP ×6 > PD transformation to DLBCL parotid > R-IVAC ×2 > PD > salvage RT to parotid† | 5 | 40 | Out (FL) |
| 14 | 83; M | DLBCL: transformed CLL | Attenuated R-CHOP ×3 > PR > salvage RT to groin* | 4 | 30 | Ongoing remission |
| 15 | 71; F | DLBCL: GCB subtype | R-CHOP ×6 > PD > salvage RT to retroperitoneum† | 5 | 45 | Ongoing remission |
| 16 | 69; M | DLBCL: ABC subtype | R-CHOP ×6 > CR > PD > salvage RT to submandibular node† | 5 | 46 | Out |
| 17 | 76; F | DLBCL: ABC subtype | R-CHOP ×6 > PD (spleen) > splenectomy† > splenic bed progression > salvage RT to splenic bed | 5 | 40 | In/out |
| 18 | 65; M | DLBCL: ABC subtype | R-CHOP ×6 > PD > salvage RT to stomach† | 5 | 50 | Out |
| No. . | Age at Dx, y; sex . | Pathology . | Treatment and response . | PET DS prior to RT . | RT dose, Gy . | Progression field (RT) . |
|---|---|---|---|---|---|---|
| 1 | 62; M | DLBCL: GCB subtype | R-CHOP ×6 > PR > salvage RT to head/neck* | 4 | 45 | Out |
| 2 | 75; M | DLBCL: GCB subtype | R-CHOP ×6 > PR > salvage RT to mediastinum† | 5 | 50 | Ongoing remission |
| 3 | 59; F | DLBCL: transformed FL | Prior multiply-relapsed FL including CHOP ×6 > transformation DLBCL > salvage chemotherapy and autograft > PD > EPOCH ×1 > CR > PD > salvage RT to S1 nerve root* | 5 | 10 (planned 44) | In/out |
| 4 | 76; M | DLBCL: GCB subtype | R-CHOP ×6 > PD > salvage RT to cecal mass† | 5 | 45 | In/out |
| 5 | 74; F | DLBCL: transformed FL | Prior FL CHOP ×6 > CR > transformation DLBCL > R-CEOP ×6 > PD > salvage RT to abdominal node‡ | 5 | 30.6 | Ongoing remission |
| 6 | 70; M | DLBCL: ABC subtype + double expressor | R-EPOCH ×6 > PD > salvage RT to maxillary progression† | 5 | 32.4 (planned 36) | Out |
| 7 | 74; M | DLBCL: ABC subtype | R-CHOP ×6 > PD > salvage RT to axilla† | 5 | 44 | Out |
| 8 | 42; M | DLBCL: GCB subtype + double expressor | R-CHOP ×3 > PD > salvage RT to inguinal node† | 5 | 50 | In/out |
| 9 | 78; F | DLBCL: GCB subtype | R-CHOP ×6 > CR > PD > salvage RT to mediastinum‡ | 5 | 40 | Ongoing remission |
| 10 | 53; M | HGBL with MYC and BCL2 and/or BCL6R | R-EPOCH ×6 > PR > salvage RT to paratracheal node‡ | 4 | 40 | Ongoing remission |
| 11 | 70; M | DLBCL: transformed FL | Prior FL > R-bendamustine > PR > PD transformation to DLBCL > salvage RT to parotid node† | 5 | 50.4 | Ongoing remission |
| 12 | 67; F | DLBCL: T cell/histiocyte rich | R-CHOP ×6 > CR > PD > GemOx > CR > PD > salvage RT to C7 vertebra* | 5 | 40 | Out |
| 13 | 48; M | DLBCL: transformed FL | Prior FL > R-CHOP ×6 > PD transformation to DLBCL parotid > R-IVAC ×2 > PD > salvage RT to parotid† | 5 | 40 | Out (FL) |
| 14 | 83; M | DLBCL: transformed CLL | Attenuated R-CHOP ×3 > PR > salvage RT to groin* | 4 | 30 | Ongoing remission |
| 15 | 71; F | DLBCL: GCB subtype | R-CHOP ×6 > PD > salvage RT to retroperitoneum† | 5 | 45 | Ongoing remission |
| 16 | 69; M | DLBCL: ABC subtype | R-CHOP ×6 > CR > PD > salvage RT to submandibular node† | 5 | 46 | Out |
| 17 | 76; F | DLBCL: ABC subtype | R-CHOP ×6 > PD (spleen) > splenectomy† > splenic bed progression > salvage RT to splenic bed | 5 | 40 | In/out |
| 18 | 65; M | DLBCL: ABC subtype | R-CHOP ×6 > PD > salvage RT to stomach† | 5 | 50 | Out |
Abbreviated treatment course is provided; full patient journeys are provided in supplemental Table 1. Progression field denotes whether patients progressed in or out of field of RT. Bold text denotes timing and site of radiotherapy.
CLL, chronic lymphocytic leukemia; CR, complete response; Dx, diagnosis; DS, Deauville score; EPOCH, etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin; F, female; FL, follicular lymphoma; GemOx, gemcitabine, oxaliplatin; HGBL, high grade B-cell lymphoma; M, male; PD, progressive disease; PR, partial response; R, rituximab; RT, radiotherapy; R-CEOP, rituximab, cyclophosphamide, etoposide, vincristine, prednisolone; R-IVAC, rituximab, ifosfamide, etoposide, cytarabine.
Biopsy was not performed, but imaging was highly suspicious for disease.
Biopsy-proven progression.
Biopsy was inconclusive.